TrialEuropean journal of cancer (Oxford, England : 1990)2017

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer.

Andrew J Armstrong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.